Healthtech startup aiming to reduce deaths caused by heat stroke secures £800k investment

Investors in this round: British Design Fund

London based startup Cryogenx, whose portable body cooling device offers a rapid response for heat-related illness, has secured a £150,000 investment from British Design Fund, as part of a wider £800,000 raise that included existing shareholders, angel investors and a US-based fund.

The company’s CGX1 device – described as an ​‘ice bath in a backpack’ – is a portable, pre-hospital core body cooling device, designed to enable rapid, life-saving cooling in any scenario. Cryogenx’s patent-pending technology features a powerful coolant stored within compact cylinders that is injected into an adhesive, thermally conductive pad placed on the patient’s torso. This emulates the effects of ice water immersion and offers a first line of treatment for anyone suffering from heat-related illness, and heatstroke in particular.

Cryogenx’s founder, Matt Anderson, first came up with idea while studying Industrial Design at Brunel University. After watching a documentary that led to a cameraman losing his life due to the effects of heat while filming in a remote location, Matt began looking into the dangers and effects of extreme heat.

An estimated 489,000 deaths globally are caused by extreme heat every year and it is likely these figures will significantly increase, as a result of rising temperatures cause by climate change.

Matt explained: “Across the world, people are suffering and dying from the effects of extreme heat and we’ve seen these figures rise, particularly in the last 5-10 years, where record temperatures have been hit across the world. The increased frequency and severity of extreme weather events, such as heatwaves, leads to a marked increase in excess mortality and could potentially be the new norm with the growing rate of extreme heat events as a result of global warming.”

He continued: “With heatstroke, the quicker you can start effectively reducing core body temperature, the more successful the treatment will be. However, in remote locations that can be very challenging.

“Cryogenx has created a portable body cooling device that can provide an immediate, on demand, solution. Our device is ideally positioned to support individuals and organisations where incidents of heat-related illness are common or likely, such as where physical labour and exposure to heat and humidity forms part of the job. This includes defence, construction, the energy sector, manufacturing industries, the fire service, sports, among many others. We are keen to connect with companies and distributors in this space to enable our technology to be in the hands of people who need it.”

The funding will support Cryogenx as it looks to initiate and ramp up its commercial activities, including completing its first formal production run. The company is also undertaking several preclinical studies, including with Brunel University and a study in the US with a leading academic in exercise and environmental physiology.

Damon Bonser, CEO at the British Design Fund, said: “Cryogenx’s technology solves a growing global need for a rapid, emergency response for heat illness. What is really impressive about the device is how well designed and thought through it is, being easily transported and operated by a single person, with no pre-preparation or specialist storage required. We look forward to working with Matt and the Cryogenx team as they bring this vital technology to market.”

British Design Fund is a leading early-stage British manufacturing investor. The Fund works with ambitious product start-up enterprises who are ready to scale-up and build thriving stand-out businesses. Alongside capital investment, BDF provides expert mentoring to support such companies to accelerate their growth plans.


Healthtech startup aiming to reduce deaths caused by heat stroke secures £800k investment

Healthtech startup aiming to reduce deaths caused by heat stroke secures £800k investment

By Amy Archer British Design Fund Profile 26 Jun 2024